APLS Stock Up 29% after 5-Day Win Streak
Apellis Pharmaceuticals (APLS) stock hit day 5 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 29% return. The company has gained about $894 Mil in value over the last 5 days, with its current market capitalization at about $3.0 Bil. The stock remains 24.0% below its value at the end of 2024. This compares with year-to-date returns of 7.6% for the S&P 500.
APLS develops therapeutic compounds targeting complement system inhibition for autoimmune and inflammatory diseases; lead product pegcetacoplan is in Phase III trials for geographic atrophy and PNH. After this rally, is APLS still a buy – or is it time to lock in gains? Deep dive with Buy or Sell APLS.
Comparing APLS Stock Returns With The S&P 500
The following table summarizes the return for APLS stock vs. the S&P 500 index over different periods, including the current streak:
- Illinois Tool Stock’s Loudest Signal Is The One It Stopped Sending
- Lumentum Stock Was Already Sold Out Before Its Big Rally
- SanDisk Stock Is Trading Like The Memory Cycle Is Dead
- The Quiet Surge In Arista Networks Stock Masks A Volatile Outlook
- The Real Risk Inside Home Depot Stock
- How Hewlett Packard Built A Fortress Out Of Its Backlog
| Return Period | APLS | S&P 500 |
|---|---|---|
| 1D | 5.7% | 1.5% |
| 5D (Current Streak) | 29.4% | -0.9% |
| 1M (21D) | 36.1% | 0.8% |
| 3M (63D) | 19.3% | 11.3% |
| YTD 2025 | -24.0% | 7.6% |
| 2024 | -46.7% | 23.3% |
| 2023 | 15.8% | 24.2% |
| 2022 | 9.4% | -19.4% |
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. However, big gains can follow sharp reversals – but how has APLS behaved after prior drops? See APLS Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 33 S&P constituents with 3 days or more of consecutive gains and 39 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 23 | 6 |
| 4D | 0 | 18 |
| 5D | 9 | 5 |
| 6D | 1 | 7 |
| 7D or more | 0 | 3 |
| Total >=3 D | 33 | 39 |
Key Financials for Apellis Pharmaceuticals (APLS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $396.6 Mil | $781.4 Mil |
| Operating Income | $-517.1 Mil | $-165.0 Mil |
| Net Income | $-528.6 Mil | $-197.9 Mil |
Last 2 Fiscal Quarters:
| Metric | 2024 FQ4 | 2025 FQ1 |
|---|---|---|
| Revenues | $212.5 Mil | $166.8 Mil |
| Operating Income | $-26.2 Mil | $-83.3 Mil |
| Net Income | $-36.4 Mil | $-92.2 Mil |
While APLS stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.